Translational Research in Alzheimer's Disease and related Dementias (TRADD)
阿尔茨海默病和相关痴呆症的转化研究 (TRADD)
基本信息
- 批准号:10709167
- 负责人:
- 金额:$ 29.45万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-01 至 2028-08-31
- 项目状态:未结题
- 来源:
- 关键词:
项目摘要
Project Summary/Abstract
The University of Arizona (UArizona) Training Program to Advance Translational Research on Alzheimer's
Disease and AD Related Dementias (AZ-TRADD) is designed to address knowledge and experience gaps in AD
therapeutic discovery and preclinical translational development. To meet this challenge, the UArizona
Translational Research in AD and related Dementias (AZ-TRADD) training program is designed as a problem
based translational learning experience for predoctoral Ph.D and M.D./Ph.D fellows. In alignment with the 2021
NIH Alzheimer’s Research Summit: Path to Precision Medicine for Treatment and Prevention and the 2011
National Alzheimer’s Project Act (NAPA), the goal of the AZ-TRADD training program is to fill critical gaps that
exist for AD translational research in academic graduate programs. To achieve this goal, the AZ-TRADD program
will: 1) recruit trainees across multiple scientific disciplines; 2) employ problem-based learning approaches to
solve challenges in AD therapeutic development with emerging tools and techniques; and 3) equip AZ-TRADD
trainees with career development and leadership skills necessary to conduct team science and manage
multidisciplinary teams. Through this approach, we ensure that AZ-TRADD trainees develop deep translational
research expertise necessary for AD therapeutic development, while: 1) cultivating the ability to creatively and
collaboratively solve problems working with experts across the translational landscape as part of large-scale
team science; 2) gaining an applied understanding of how data science, particularly using data generated by
AMP-AD, M2OVE-AD and ADNI, can accelerate translational research and provide avenues to novel therapeutic
insights; 3) connecting geno- and phenotypic variations and multifaceted etiology of AD to therapeutic targets;
and 4) gaining essential professional and business skills to navigate a diverse funding landscape and translate
discoveries into the clinical setting. AZ-TRADD fellows will receive career mentoring and leadership development
skills to manage multi-disciplinary teams in the 21st century that is Patient Inspired and Data Driven. The AZ-
TRADD training program will develop a diverse, cross-disciplinary, and translationally oriented workforce to meet
the critical challenge of creating a workforce capable of advancing therapeutics to prevent, delay, and treat AD
and AD related dementias.
项目总结/摘要
亚利桑那大学(UArizona)培训计划,以推进阿尔茨海默氏症的转化研究
疾病和AD相关痴呆(AZ-TRADD)旨在解决AD的知识和经验差距
治疗发现和临床前转化开发。为了应对这一挑战,亚利桑那大学
AD和相关痴呆的转化研究(AZ-TRADD)培训计划是作为一个问题而设计的
博士前博士和医学博士的翻译学习经验/博士研究员。为了配合2021年
NIH阿尔茨海默氏症研究峰会:治疗和预防的精准医学之路以及2011年
国家阿尔茨海默病项目法案(NAPA),AZ-TRADD培训计划的目标是填补关键空白,
存在于学术研究生课程中的AD转化研究。为了实现这一目标,AZ-TRADD计划
将:1)招募跨多个科学学科的受训人员; 2)采用基于问题的学习方法,
用新兴工具和技术解决AD治疗开发中的挑战; 3)装备AZ-TRADD
具有职业发展和领导技能的学员,以进行团队科学和管理
多学科团队。通过这种方法,我们确保AZ-TRADD学员能够培养深度翻译能力,
AD治疗开发所需的研究专业知识,同时:1)培养创造性和
作为大规模翻译工作的一部分,
团队科学; 2)获得对数据科学如何应用的理解,特别是使用
AMP-AD、M2 OVE-AD和ADNI可以加速转化研究,并为开发新的治疗药物提供途径。
3)将基因型和表型变异以及AD的多方面病因学与治疗靶点联系起来;
以及4)获得必要的专业和商业技能,以驾驭多样化的融资环境,并将其转化为
将新发现应用于临床。AZ-TRADD研究员将获得职业指导和领导力发展
在21世纪管理多学科团队的技能,即患者启发和数据驱动。AZ-
TRADD培训计划将培养一支多元化、跨学科和专业化的员工队伍,以满足
创建一支能够推进预防、延迟和治疗AD疗法的工作队伍的关键挑战
以及AD相关痴呆症。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ROBERTA EILEEN BRINTON其他文献
ROBERTA EILEEN BRINTON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ROBERTA EILEEN BRINTON', 18)}}的其他基金
Novel Intranasal Formulations of Allopregnanolone, a Regenerative Therapeutic for Alzheimer's Disease
Allopregnanolone 的新型鼻内制剂,一种阿尔茨海默病的再生疗法
- 批准号:
10698555 - 财政年份:2023
- 资助金额:
$ 29.45万 - 项目类别:
PhytoSERM Efficacy to Prevent Menopause Associated Decline in Brain Metabolism and Cognition: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Clinical Trial
PhytoSERM 预防更年期相关脑代谢和认知能力下降的功效:双盲、随机、安慰剂对照 2 期临床试验
- 批准号:
10560591 - 财政年份:2022
- 资助金额:
$ 29.45万 - 项目类别:
PhytoSERM Efficacy to Prevent Menopause Associated Decline in Brain Metabolism and Cognition: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Clinical Trial
PhytoSERM 预防更年期相关脑代谢和认知能力下降的功效:双盲、随机、安慰剂对照 2 期临床试验
- 批准号:
10344556 - 财政年份:2022
- 资助金额:
$ 29.45万 - 项目类别:
PhytoSERM for Menopausal Hot Flashes and Sustained Brain Health
PhytoSERM 针对更年期潮热和持续大脑健康
- 批准号:
10547639 - 财政年份:2022
- 资助金额:
$ 29.45万 - 项目类别:
PhytoSERM for Menopausal Hot Flashes and Sustained Brain Health
PhytoSERM 针对更年期潮热和持续大脑健康
- 批准号:
10707107 - 财政年份:2022
- 资助金额:
$ 29.45万 - 项目类别:
Regulatory and Human Study Operations (RHSO) Core C
监管和人体研究运营 (RHSO) 核心 C
- 批准号:
10689308 - 财政年份:2021
- 资助金额:
$ 29.45万 - 项目类别:
Regulatory and Human Study Operations (RHSO) Core C
监管和人体研究运营 (RHSO) 核心 C
- 批准号:
10491851 - 财政年份:2021
- 资助金额:
$ 29.45万 - 项目类别:
Regulatory and Human Study Operations (RHSO) Core C
监管和人体研究运营 (RHSO) 核心 C
- 批准号:
10270190 - 财政年份:2021
- 资助金额:
$ 29.45万 - 项目类别:
Undergraduate Readying for Burgeoning Research for American Indian Neuroscientists
本科生为美洲印第安人神经科学家的新兴研究做好准备
- 批准号:
10199069 - 财政年份:2019
- 资助金额:
$ 29.45万 - 项目类别: